NASDAQ:ASRT Assertio - ASRT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.00 +0.22 (+3.81%) (As of 03/21/2023 01:45 PM ET) Add Compare Share Share Today's Range$5.86▼$6.0550-Day Range$3.54▼$6.6652-Week Range$1.86▼$7.00Volume818,299 shsAverage Volume1.96 million shsMarket Capitalization$333.48 millionP/E Ratio3.37Dividend YieldN/APrice Target$7.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Assertio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside24.4% Upside$7.50 Price TargetShort InterestHealthy9.64% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth37.25%From $0.51 to $0.70 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector110th out of 988 stocksPharmaceutical Preparations Industry34th out of 482 stocks 2.5 Analyst's Opinion Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Assertio has a forecasted upside of 24.4% from its current price of $6.03.Amount of Analyst CoverageAssertio has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted9.64% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assertio has recently decreased by 43.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASRT. Previous Next 3.0 News and Social Media Coverage News SentimentAssertio has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Assertio this week, compared to 3 articles on an average week.Search Interest46 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 24% compared to the previous 30 days.MarketBeat Follows14 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Assertio is held by insiders.Percentage Held by InstitutionsOnly 33.31% of the stock of Assertio is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Assertio are expected to grow by 37.25% in the coming year, from $0.51 to $0.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is 3.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is 3.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 95.39.Price to Earnings Growth RatioAssertio has a PEG Ratio of 1.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAssertio has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Assertio (NASDAQ:ASRT) StockAssertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.Read More Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address ASRT Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comStockNews.com Upgrades Assertio (NASDAQ:ASRT) to BuyMarch 13, 2023 | americanbankingnews.comAssertio (NASDAQ:ASRT) Downgraded to Hold at StockNews.comMarch 21, 2023 | PressReach (Ad)This Stock Has Room To RunAnalysts believe this stock's product demand could rise quickly in the next few years.March 10, 2023 | finance.yahoo.comAssertio Holdings, Inc. (NASDAQ:ASRT) Q4 2022 Earnings Call TranscriptMarch 8, 2023 | finance.yahoo.comAssertio Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 6, 2023 | finance.yahoo.comAssertio Appoints Dr. Howard Franklin as Senior Vice President, MedicalMarch 3, 2023 | finance.yahoo.comAssertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should KnowMarch 2, 2023 | finance.yahoo.comWhy Earnings Season Could Be Great for Assertio (ASRT)March 21, 2023 | Press Research (Ad)Stocks For Smart InvestorsThis under-the-radar stock is in the right industry at the perfect time.March 1, 2023 | finance.yahoo.comAssertio Holdings, Inc.'s (NASDAQ:ASRT) Intrinsic Value Is Potentially 40% Above Its Share PriceFebruary 23, 2023 | finance.yahoo.comAssertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027February 21, 2023 | finance.yahoo.comAssertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 ResultsFebruary 20, 2023 | finance.yahoo.comAssertio Holdings, Inc. (ASRT) Is a Trending Stock: Facts to Know Before Betting on ItFebruary 16, 2023 | finance.yahoo.comAssertio to Participate in the 2023 Winter Wonderland Best Ideas ConferenceFebruary 13, 2023 | finance.yahoo.comAssertio (ASRT) to Report Q4 Earnings: What's in the Cards?February 9, 2023 | finance.yahoo.comIs Assertio Holdings, Inc.'s (NASDAQ:ASRT) Latest Stock Performance A Reflection Of Its Financial Health?February 8, 2023 | finance.yahoo.comAssertio to Participate in the 2023 SVB Securities Global Biopharma ConferenceFebruary 8, 2023 | finance.yahoo.comInvestors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to KnowJanuary 30, 2023 | stocknews.com4 Stocks to Buy for Under $8 in 2023January 22, 2023 | seekingalpha.comAssertio Holdings Scores With New Broadly-Covered AssetJanuary 17, 2023 | finance.yahoo.comAssertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) FoundationJanuary 9, 2023 | finance.yahoo.comAssertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film PatentDecember 30, 2022 | finance.yahoo.comAssertio Holdings (NASDAQ:ASRT) shareholders have endured a 88% loss from investing in the stock five years agoDecember 21, 2022 | finance.yahoo.comAfter Golden Cross, Assertio (ASRT)'s Technical Outlook is BrightDecember 15, 2022 | finance.yahoo.comAre Medical Stocks Lagging Assertio (ASRT) This Year?December 13, 2022 | finance.yahoo.comAssertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San FranciscoDecember 5, 2022 | finance.yahoo.comAssertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 MillionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address ASRT Company Calendar Last Earnings11/04/2021Today3/21/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASRT CUSIPN/A CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees19Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$8.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+29.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.78 Trailing P/E Ratio3.25 Forward P/E Ratio11.33 P/E Growth1.14Net Income$109.63 million Net Margins70.17% Pretax Margin19.95% Return on Equity72.98% Return on Assets31.36% Debt Debt-to-Equity Ratio0.29 Current Ratio1.39 Quick Ratio1.24 Sales & Book Value Annual Sales$156.23 million Price / Sales2.06 Cash Flow$2.95 per share Price / Cash Flow1.96 Book Value$4.67 per share Price / Book1.24Miscellaneous Outstanding Shares55,580,000Free Float54,190,000Market Cap$321.25 million OptionableOptionable Beta1.38 Key ExecutivesDaniel A. PeisertPresident, Chief Executive Officer & DirectorWilliam IskosSenior Vice President-OperationsPaul SchwichtenbergChief Financial Officer & Senior Vice PresidentAjay PatelChief Accounting Officer & Senior Vice PresidentSam SchlessingerSenior Vice President & General CounselKey CompetitorsKezar Life SciencesNASDAQ:KZRPrelude TherapeuticsNASDAQ:PRLDNGM BiopharmaceuticalsNASDAQ:NGMTheseus PharmaceuticalsNASDAQ:THRXCara TherapeuticsNASDAQ:CARAView All CompetitorsInsiders & InstitutionsSusquehanna Fundamental Investments LLCSold 12,693 shares on 2/15/2023Ownership: 0.493%Schonfeld Strategic Advisors LLCSold 6,700 shares on 2/15/2023Ownership: 0.204%Squarepoint Ops LLCBought 10,414 shares on 2/15/2023Ownership: 0.047%Boothbay Fund Management LLCBought 15,132 shares on 2/15/2023Ownership: 0.031%Stokes Family Office LLCBought 13,699 shares on 2/15/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions ASRT Stock - Frequently Asked Questions Should I buy or sell Assertio stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assertio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASRT shares. View ASRT analyst ratings or view top-rated stocks. What is Assertio's stock price forecast for 2023? 3 analysts have issued 1 year target prices for Assertio's stock. Their ASRT share price forecasts range from $7.00 to $8.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price. View analysts price targets for ASRT or view top-rated stocks among Wall Street analysts. How have ASRT shares performed in 2023? Assertio's stock was trading at $4.30 at the beginning of 2023. Since then, ASRT stock has increased by 34.4% and is now trading at $5.78. View the best growth stocks for 2023 here. Are investors shorting Assertio? Assertio saw a drop in short interest in February. As of February 28th, there was short interest totaling 5,360,000 shares, a drop of 43.2% from the February 13th total of 9,440,000 shares. Based on an average trading volume of 1,590,000 shares, the days-to-cover ratio is currently 3.4 days. View Assertio's Short Interest. When is Assertio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our ASRT earnings forecast. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.12. The business earned $25.47 million during the quarter, compared to analyst estimates of $22.04 million. Assertio had a net margin of 70.17% and a trailing twelve-month return on equity of 72.98%. During the same period in the previous year, the business posted ($0.36) EPS. What ETF holds Assertio's stock ? Hartford Multifactor Small Cap ETF holds 55,110 shares of ASRT stock, representing 0.74% of its portfolio. What guidance has Assertio issued on next quarter's earnings? Assertio updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $36.00 million-$38.00 million, compared to the consensus revenue estimate of $37.59 million. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assertio investors own include Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Cerecor (CERC) and OPKO Health (OPK). What is Assertio's stock symbol? Assertio trades on the NASDAQ under the ticker symbol "ASRT." Who are Assertio's major shareholders? Assertio's stock is owned by a number of retail and institutional investors. Top institutional investors include Millennium Management LLC (1.95%), Renaissance Technologies LLC (1.71%), First Eagle Investment Management LLC (1.42%), Marshall Wace LLP (1.38%), Two Sigma Investments LP (1.17%) and American Century Companies Inc. (0.93%). Insiders that own company stock include Ajay Patel, Daniel A Peisert, Group LP Cr, James L Tyree, Karen A Dawes and Paul Schwichtenberg. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Assertio's stock price today? One share of ASRT stock can currently be purchased for approximately $5.78. How much money does Assertio make? Assertio (NASDAQ:ASRT) has a market capitalization of $321.25 million and generates $156.23 million in revenue each year. The company earns $109.63 million in net income (profit) each year or $1.78 on an earnings per share basis. How can I contact Assertio? Assertio's mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The official website for the company is www.assertiotx.com. The company can be reached via phone at (224) 419-7106, via email at investor@assertiotx.com, or via fax at 510-744-8001. This page (NASDAQ:ASRT) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.